SINGAPORE – Asia has all the building blocks necessary to be at the vanguard of drug innovation, so what is stopping it from being on an equal footing with mature markets such as the U.S. and Europe? Industry experts at the 2017 BioPharma Asia Convention pointed to the need for a change in the region’s mindset toward innovation.
SINGAPORE – Asia’s rapidly developing health care ecosystem should ease market access for pharmaceutical companies and drug access for patients, but communication and transparency remain a key challenge hindering development. Unless all stakeholders in the sector come together, drug costs will remain high, industry experts said at the BioPharma Asia Convention.
HONG KONG – To facilitate the growth of pharmaceutical markets and expedite drug approvals throughout the 10-country Association of Southeast Asian Nations (ASEAN), a consistent regulatory system is needed.
HONG KONG – To facilitate the growth of pharmaceutical markets and expedite drug approvals throughout the 10-country Association of Southeast Asian Nations (ASEAN), a consistent regulatory system is needed.
SINGAPORE – Asia has all the building blocks necessary to be at the vanguard of drug innovation, so what is stopping it from being on an equal footing with mature markets such as the U.S. and Europe? Industry experts at the 2017 BioPharma Asia Convention in Singapore pointed to the need for a change in the region's mindset toward innovation.
SINGAPORE – Asia's rapidly developing health care ecosystem should ease market access for pharmaceutical companies and drug access for patients, but communication and transparency remain a key challenge hindering development. Unless all stakeholders in the sector come together, drug costs will remain high, industry experts said at the BioPharma Asia Convention here.
HONG KONG – Malaysia-based CCM Duopharma Biotech Bhd is positioning itself to capitalize on the growing biosimilars market in Southeast Asia (SEA), following the success of a phase III trial of its erythropoietin (EPO) biosimilar for kidney dialysis. The Kuala Lumpur-based company is set to commence registration of the drug and further strengthen its position in the Malaysian market.
HONG KONG – The CFDA has issued a new rule that cuts the timing and pricing gaps between overseas and domestic drug launches, which is likely to improve access to innovative drugs for patients and accelerate drugmakers' strategies in China.
HONG KONG – The CFDA has issued a new rule that cuts the timing and pricing gaps between overseas and domestic drug launches, which is likely to improve access to innovative drugs for patients and accelerate drugmakers' strategies in China.
